Clinical Trial Update: HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of Sacituzumab Govitecan in HR+/HER2- advanced or metastatic breast cancer (Stage IV) that is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Breast Cancer Stage IV | Phase 2 | Status: RECRUITING